AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
Completed
- Conditions
- Acute Coronary Syndromes
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 418
- Registration Number
- NCT01061086
- Locations
- 🇬🇷
Research Site, Chios, Greece
Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT01058447
A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT01055691
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Statin Therapy Results in the Real World Practice in the Czech Republic
Completed
- Conditions
- Dyslipidaemia
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3253
- Registration Number
- NCT01055977
- Locations
- 🇨🇿
Research Site, Znojmo, Czech Republic
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01055652
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Evaluation of Target Organs Damage in Hypertensive Patients
Completed
- Conditions
- Target Organs DamageHypertensiveno Known Cardiovascularno Known Renal Disease
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1857
- Registration Number
- NCT01055353
- Locations
- 🇫🇷
Research Site, Yvre L Eveque, France
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01054170
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT01051505
- Locations
- 🇬🇧
Research Site, London Bridge, United Kingdom
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT01049360
- Locations
- 🇺🇸
Forest Investigative Site 1121, Spartanburg, South Carolina, United States
🇺🇸Forest Investigative Site 1152, Clearwater, Florida, United States
🇺🇸Forest Investigative Site 2029, Rancho Mirage, California, United States
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 251
- Registration Number
- NCT01047553
- Locations
- 🇯🇵
Research Site, Kyoto, Japan